https://www.youtube.com/watch?v=uuAjGLk4iTQ



Pfizer Defense Against Vaccine Fraud Case: Federal Contract Status Offers Them Immunity

10:46 video runtime

TrialSite News

Join The Conversation! | https://trialsitenews.com/
Pfizer has proposed in their defense in a lawsuit charging them with vaccine study fraud that there cannot be any legal culpability associated with the charged violations associated with certifications to the federal government as part of their contract in response to the COVID-19 pandemic. Why? Because a federal contract status offers them immunity from such claims. As part of the whistleblower Brook Jackson’s lawsuit against Pfizer, the pharmaceutical company seeks to dismiss the case.


__________________
https://www.trialsitenews.com/a/pfiz...rules-02546b23

Pfizer Defense Against Vaccine Fraud Case: Does the 'Other Transaction Authority' Contractual Exemption Grant Pfizer a Pass?

TrialSite Staff
Staff at TrialSite | Quality Journalism
Jun. 11, 2022, 11:04 a.m.

Pfizer has proposed in their defense in a lawsuit charging them with vaccine study fraud that there cannot be any legal culpability associated with the charged violations associated with certifications to the federal government as part of their contract in response to the COVID-19 pandemic. Why? Because a federal contract status offers them immunity from such claims. As part of the whistleblower Brook Jackson’s lawsuit against Pfizer, the pharmaceutical company seeks to dismiss the case.

According to the legal defense, Pfizer could effectively lie to the government about safety or efficacy issues “because the government was in on it with them,” reports attorney Robert Barnes. The lawsuit is associated with the whistleblower Brook Jackson, who was interviewed by Sonia Elijah on TrialSite. While Ms. Jackson worked for a contract research organization called Ventavia Research Group (Ventavia) on the pivotal Phase 3 Pfizer COVID-19 vaccine study, she alleges that she witnessed many critical, compliance-violating anomalies needing immediate attention. Ms. Jackson emailed the complaint concerning alleged violations of good clinical practices as well as various compliance frameworks and laws to the U.S. Food and Drug Administration (FDA) in September 2020, however, the executive branch agency in charge of enforcement of alleged violations opted to not even open an investigation. The study continued, and Pfizer didn’t make any adjustments working with Ventavia. But the CRO did sack Ms. Jackson for alleging that they were involved with fraudulent manipulation of data and other allegations.